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Abstract
Background: Although evidence suggests that the prevalence of Parkinson’s disease (PD) is lower in smokers than in
non-smokers, the mechanisms of nicotine-induced neuroprotection remain unclear. Stimulation of the α7 nicotinic
acetylcholine receptor (α7-nAChR) seems to be a crucial mechanism underlying the anti-inflammatory potential of
cholinergic agonists in immune cells, including astrocytes, and inhibition of astrocyte activation has been proposed as
a novel strategy for the treatment of neurodegenerative disorders such as PD. The objective of the present study was
to determine whether nicotine-induced neuroprotection in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
mouse model occurs via α7-nAChR-mediated inhibition of astrocytes.
Methods: Both in vivo (MPTP) and in vitro (1-methyl-4-phenylpyridinium ion (MPP+) and lipopolysaccharide (LPS)) models
of PD were used to investigate the role(s) of and possible mechanism(s) by which α7-nAChRs protect against
dopaminergic neuron loss. Multiple experimental approaches, including behavioral tests, immunochemistry, and
stereology experiments, astrocyte cell cultures, reverse transcriptase PCR, laser scanning confocal microscopy, tumor
necrosis factor (TNF)-α assays, and western blotting, were used to elucidate the mechanisms of the α7-nAChR-mediated
neuroprotection.
Results: Systemic administration of nicotine alleviated MPTP-induced behavioral symptoms, improved motor
coordination, and protected against dopaminergic neuron loss and the activation of astrocytes and microglia in the
substantia nigra. The protective effects of nicotine were abolished by administration of the α7-nAChR-selective antagonist
methyllycaconitine (MLA). In primary cultured mouse astrocytes, pretreatment with nicotine suppressed MPP+-induced or
LPS-induced astrocyte activation, as evidenced by both decreased production of TNF-α and inhibition of extracellular
regulated kinase1/2 (Erk1/2) and p38 activation in astrocytes, and these effects were also reversed by MLA.
Conclusion: Taken together, our results suggest that α7-nAChR-mediated inhibition of astrocyte activation is an
important mechanism underlying the protective effects of nicotine.
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Background
Administration of the neurotoxin 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) to establish various ani-
mal models of Parkinson’s disease (PD) has proved to be
valuable in the analysis of crucial aspects of this neurode-
generative disease. A metabolite of MPTP in astrocytes, 1-
methyl-4-phenylpyridinium ion (MPP+), is known to block
mitochondrial complex I and to lead to the selective dopa-
minergic neurodegeneration that is also present in PD [1].
Astrocytes, the most abundant glial cell population, are of
neuroectodermal origin, and are thought to be essential for
brain homeostasis and neuronal function [2]. Evidence sug-
gests that there is enhanced immunoreactivity of glial fibril-
lary acidic protein (GFAP) in the striatum and substantia
nigra (SN) of patients with PD and in mice treated with
MPTP. In the MPTP mouse model, astrocyte activation
has been found to be concomitant with neuronal death [3-
5].
Studies have shown that after neuronal injury, reactive
astrocytes can facilitate neuronal destruction by synthe-
sizing and releasing pro-inflammatory cytokines, which
can damage local neurons [2]. Reactive astrocytes can
also actively contribute to secondary degeneration after
CNS insults or in response to inflammatory signaling
cues [6]. Consequently, drugs that can inhibit astrocyte
activation and the subsequent inflammatory processes
may assist in providing new insights into the intrinsic
capacity of the CNS to endure pathogenic insults, and
can aid in the identification of molecular targets for
therapeutic interventions in a variety of neuroinflamma-
tory and neurodegenerative diseases such as PD [2].
Epidemiologic studies have shown that the prevalence of
PD is lower in smokers than in non-smokers. Nicotine, a
potent agonist to nicotinic acetylcholine receptors
(nAChRs), may exert anti-parkinsonian effects [7]. Recent
studies suggest that the ‘nicotinic anti-inflammatory path-
way’ may have important clinical implications, as treatment
with nicotinic agonists can potentially modulate the pro-
duction of pro-inflammatory cytokines from immune cells
via interactions at α7-containing nAChRs (α7-nAChRs).
Thus, α7-nAChRs may serve as a crucial link between in-
flammation and neurodegeneration in PD and could repre-
sent a pharmacological target for potential induction of
neuroprotection [8].
In the present study, the main objective was to deter-
mine, using in vivo and in vitro models, whether nicotine,
acting at α7-nAChRs, could inhibit astrocyte-mediated
neuroinflammation triggered by MPTP/MPP+, thus po-
tentially preventing dopaminergic neurodegeneration. The
potential anti-inflammatory mechanism(s) and regulation
of astrocyte activation by nicotine were further investi-
gated using lipopolysaccharide (LPS), which is the most
extensively used glial cell activator because of its induction
of inflammatory changes and consequent dopaminergic
neurodegeneration [9]. Furthermore, we investigated
whether α7-nAChR function is associated with modulation
of phosphorylation of extracellular regulated kinase1/2
(Erk1/2) and p38 mitogen-activated protein kinases
(MAPKs).
Methods
Animals and treatments
All experiments were carried out in accordance with the
National Institutes of Health Guide for the Care and Use of
Laboratory Animals (publication number 85–23, revised
1985) and the Society for Neuroscience Guidelines for the
Care and Use of Animals in Neuroscience Research, and
were approved by the Institutional Animal Care and Use
Committee of Nanjing Medical University [5].
Male C57BL/6 black mice (8 to 10-weeks old, weigh-
ing 24 to 28 g) were used. All animals were housed in
groups of five per cage under standard laboratory condi-
tions with free access to food and water, constant room
temperature (22°C) and humidity (50 to 60 %), and a
natural day/night cycle.
Nicotine, methyllycaconitine citrate (MLA), and
MPTP were dissolved in sterile saline (0.9 % NaCl). Mice
were randomly divided into different groups as described
below. All drugs were obtained from Sigma Chemical
Co. (St. Louis, MO, USA).
Control mice received saline only. Mice in the treat-
ment group received four intraperitoneal injections of
MPTP-HCl 20 mg/kg at 2-hour intervals on the same
day. For nicotine treatment, mice were given intraperito-
neal injections of nicotine (0.25 or 0.5 mg/kg) five times
a day at 2-hour intervals over a 2-week period (1 week
before, during, and 1 week after MPTP administration).
The nicotine was injected 30 minutes before each MPTP
injection. MLA 5.0 mg/kg, used for nicotine antagonism
studies, was injected 30 minutes before nicotine admin-
istration twice a day for 2 weeks (1 week before, during,
and 1 week after MPTP administration) [10,11]. Further-
more, cohorts of mice were treated with nicotine
0.5 mg/kg or MLA 5.0 mg/kg alone five times a day at
2-hour intervals for 2 weeks to observe whether those
drugs alone influenced behavioral symptoms, dopamin-
ergic neuron degeneration, and/or astrocyte activation.
Behavioral tests
The effects of MPTP on movement were evaluated by a
pole test [3]. Briefly, a cork ball (diameter 25 mm) was
fixed to the top of a vertical, wooden rough-surfaced
pole (diameter 10 mm, height 500 mm). The mouse was
placed head upward on the cork ball, and the following
activities were recorded: turning downward on the ball,
climbing down the upper half of the pole, climbing
down the lower half of the pole. The activities were
scored as follows: 3 for recorded times of less than 3
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seconds, 2 if less than 6 seconds, and 1 if less than 6 sec-
onds. Results were expressed as the total score.
Immunochemistry and stereology
Animals were anaesthetized using chloral hydrate, and
perfused with 0.9% NaCl, followed by cold 4% parafor-
maldehyde in 0.1 mol/l phosphate buffer (pH 7.4). The
brains were dissected out and maintained in 4 % parafor-
maldehyde overnight. Brains were cryopreserved in 30%
sucrose in PBS and stored at −70°C until required. Free-
floating sections encompassing the entire midbrain were
cut on a cryostat. Sections were processed for tyrosine
hydroxylase (TH), GFAP, and Mac-1 (marker for micro-
glia [4]) immunohistochemistry as described below.
After incubation for 1 h in 10 % BSA with 0.3% Triton
X-100 in 0.01 mol/l PBS, the tissue sections (30 mm)
were incubated with primary antibodies overnight at
4°C. The primary antibodies used in this study were a
mouse antibody against TH (1:3000, Sigma Chemical
Co.), goat antibody against GFAP (1:1000; Millipore
Corp., Billerica, MA, USA), and rat anti-mouse Mac-1
polyclonal antibody (1:100, CD11b, AbD; Serotec,
Oxford, UK). Immunostaining was visualized by using
3,3′-diaminobenzidine, and sections were then coun-
terstained with hematoxylin [5,6,12].
All cell counts were performed by researchers blinded
to the experimental status of the animals. The total
number of TH-immunoreactive (IR) neurons, GFAP-IR
astrocytes, and Mac-1-IR microglia in the substantia
nigra pars compacta (SNpc) were counted from six mice
per group using an optical fractionator [13], which is an
unbiased method of cell counting that is not affected by
either the volume of reference or the size of the counted
elements (Stereo Investigator software, Microbrightfield,
Colchester, VT, USA). In this method, TH-IR neurons,
GFAP-IR astrocytes, and Mac-1-IR microglia were
counted in the SNpc of every fourth section (30 mm)
throughout the entire extent of the SNpc. Each midbrain
section was viewed at low power (×10 objective), and
the SNpc was outlined in accordance with the estab-
lished anatomical landmark. Then, at a random starting
point, the number of TH-positive neurons, GFAP-
positive astrocytes and Mac-1-IR microglia were counted
at high power (×100, oil immersion). To avoid double
counting of cells with unusual shapes, each type of cell
(TH-IR neurons, GFAP-IR astrocytes and Mac-1-IR
microglia) was counted only when its nucleus were opti-
mally visualized, which occurred in only one focal plane.
After all the appropriate cells were counted, the total
numbers of TH-IR neurons, GFAP-IR astrocytes, and
Mac-1-IR microglia in the SNpc were calculated using
the formula described by West [13]. Sampling grid
dimensions were 120 × 120 x 5 mm (x, y, and z axes,
respectively).
Astrocyte cell cultures
Primary cultures of mouse astrocytes were prepared
from the midbrain of C57BL/6 black newborn mice 1 to
2 days after birth as previously described [6]. In brief,
the mid brain was dissected under sterile conditions and
the meninges were carefully removed. Brain tissues were
dissociated in 0.25% trypsin (Gibco) for 10 minutes at
37°C. The cell suspension was separated by centrifuga-
tion at 240 g for 5 minutes, and the cells were trans-
ferred to poly-D-lysine pre-coated cell culture flasks in
DMEM containing 10% FCS, 100 U/ml penicillin and
100 μg/ml streptomycin. The cultures were maintained
at 37°C in a humidified atmosphere of 5% CO2 and 95%
air. Before the experiments, analyses showed that over
95% of the cells stained positively for the astrocytic mar-
ker GFAP (1:800; Abcam, Cambridge, MA, USA). All
experiments were performed after approximately 12 to
15 days in culture.
Staining with α-bungarotoxin and confocal microscopy
Primary cultured astrocytes (as described above) were
passaged in six-well tissue-culture plates at 5 × 105 cells
per well, and then cultured for 24 hours. Thereafter, cul-
tures were incubated with Alexa Fluor 488-conjugated
α-bungarotoxin (2.5 μg/ml; B13422, Invitrogen Corp.,
OR, USA) at 4°C for 15 minutes. Immediately after incu-
bation, these cells were washed with PBS three times,
and then fixed for 15 minutes in 4% paraformaldehyde
in PBS at room temperature. After fixation, cells were
washed once with PBS and then mounted for viewing
under a laser scanning confocal microscope (Meta 710
Laser Scanning Microscope, Carl Zeiss Inc., Thornwood,
NY, USA).
Reverse transcription-polymerase chain reaction and
real-time PCR
For RNA extraction and reverse transcription (RT)-
PCR, total RNA was isolated (RNAisoTM Plus;
TaKaRa Biotechnology, Dalian, China) from the SN
brain region of mice after drug treatment. First-strand
cDNA was synthesized from total RNA using a first-
strand cDNA synthesis kit (TaKaRa Biotechnology) in
accordance with the manufacturer’s instructions. PCR
was performed on the equivalent cDNAs from each
sample. Amplification was performed with the primer
sets shown in Table 1. The thermal cycling conditions
for both sets of primers were 94°C for 5 minutes, fol-
lowed by 30 cycles of 94°C for 30 seconds, 57°C for
30 seconds, and 72°C for 45 seconds, with a final ex-
tension step at 72°C for 10 minutes. The PCR products
were then separated in a 3% agarose gel containing eth-
idium bromide, and analyzed using a gel imaging system
(model 3500, Tanon Science and Technology Co., Shang-
hai, China). Each real-time PCR reaction was carried out
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in triplicate in a total volume of 20 μl with SYBR Green
(Premix Ex TaqTM; TaKaRa Biotechnology, Dalian, China)
under the following conditions: stage 1, 95°C for 30 sec-
onds (1 cycle); stage 2, 95°C for 5 seconds and 60°C for 20
seconds (40 cycles). Determination of the cycle threshold
(Ct) value in a PCR amplification curve was performed
using a real-time PCR system (LightCycler; Roche Diag-
nostics, Basel, Switzerland).
Tumor necrosis factor-α assay
Nicotine, LPS, MPP+ and MLA were dissolved in buf-
fered Hank’s buffered salt solution at neutral pH (7.0).
All drugs were obtained from Sigma Chemical Co.. Cells
were plated onto 12-well plates (1.5 ml, 1 × 106/well),
and allowed to adhere for 24 hours at 37°C before being
subjected to various treatments. When performing treat-
ments, we used FCS-free DMEM, and the amount of
TNF-α in the culture medium was determined 24 hours
after treatment using a mouse TNF-α ELISA kit (Beijing
4A Biotech Co. Ltd., Beijing, China) [12].
Western blotting
Cells were collected and homogenized in 200 μl lysis buffer.
After incubation for 20 minutes on ice, cell lysates were
separated by centrifugation, and the protein concentration
in the extracts was determined by the Bradford assay. Pro-
teins in the cell extracts were denatured with SDS sample
buffer and separated by 10% SDS-PAGE. Proteins were
transferred to nitrocellulose membranes using a wet trans-
fer unit (Miniprotein-III; Bio-Rad Laboratories, Inc.,
Hercules, CA, USA). The membranes were incubated with
5% BSA dissolved in Tris-buffered saline with Tween 20
(TBS-T, 10 mmol/l Tris–HCl, 150 mmol/l NaCl, and
0.1% Tween 20, pH 7.5)) at room temperature for 1
hour, washed three times, and incubated with differ-
ent antibodies (Erk1/2, phosphor-Erk1/2, p38 and
phospho-p38, 1:1000; Cell Signaling Technology Inc.,
Beverly, MA USA; α7-nAChRs, 1:300, Santa Cruz
Biotechnology Inc., Santa Cruz, CA USA) overnight
at 41°C. The membranes were washed three times
with TBS-T buffer, and incubated with secondary
antibody for 1 hour, followed by four washes in
TBS-T. Signal detection was performed with an
enhanced chemiluminescence kit [6,12]. The results
were scanned using a gel imaging system (GelMax
Imager; Ultra-Violet Products Ltd., Upland, CA,
USA) and measured using analyzing software (Gel-
Pro Analyzer software; Media Cybernetics, Inc.,
Bethesda, MD, USA).
Statistical analyses
All values are expressed as mean ± standard error of the
mean (SEM). Differences between means were analyzed
using one-way or two-way ANOVA with time and treat-
ment as the independent factors. When ANOVA showed
significant differences, pairwise comparisons between
means were further analyzed using the Newman-Keuls
post hoc test. In all analyses, significance was set at
P= 0.05 [3,5].
Results
Nicotine alleviates 1-methyl-4-phenyl-1,2,3,
6-tetrahydropyridine-induced deficits in motor
coordination
To assess the effects of nicotine on motor function in mice,
we used the pole test. Mice were examined under baseline
conditions and at 3 hours, 1 day, 2 days and 7 days after
MPTP injection. Deficits in motor coordination clearly
were seen in MPTP-treated mice at 3 hours, 1 day and
2 days after drug administration. On day 7, there was par-
tial recovery of impaired motor function. Administration of
nicotine 0.5 mg/kg significantly increased the performance
scores of MPTP-treated mice on days 1, 2 and 7 compared
with mice treated with MPTP alone. In particular, on day 2,
mice treated with both MPTP and nicotine achieved similar
pole-test scores to those of saline-treated control mice, sug-
gesting that nicotine alleviated the MPTP-induced deficits
in motor coordination. There was no significant difference
in motor performance of mice treated with saline compared
with those receiving nicotine alone (Figure 1).
Nicotine acting via α7-nicotinic acetylcholine receptors
prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-
induced dopaminergic neuron loss in the substantia nigra
pars compacta
Stereological counts of TH-IR cells in the SNpc were
undertaken to explore the effects of nicotine on
MPTP-induced degeneration of dopaminergic neurons.
Table 1 Primers used for amplification
Name Genbank accession number Direction Sequence, 5′→3′ Size of product bp
GADPH NM_008084.2 Forward TGTGTCCGTCGTGGATCTGA 150
Reverse TTGCTGTTGAAGTCGCAGGAG
α7 subunit NM 007390.3 Forward AACCATGCGCCGTAGGACA 172
Reverse CTCAGCCACAAGCAGCATGAA
GADPH, glyceraldehyde-3-phosphate dehydrogenase.
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Dopaminergic neurons in the SNpc were intensely immu-
noreactive to TH in control (saline-only) mice (Figure 2A).
Treatment with MPTP significantly reduced the numbers
of TH-IR neurons by 42.5±4.2% compared with controls.
However, in mice treated with both MPTP and nicotine
0.5 mg/kg, dopaminergic neurons were reduced by only
11.3±2.0% compared with controls (P> 0.05). The differ-
ence in the numbers of TH-IR neurons between mice trea-
ted with MPTP alone and those treated with both MPTP
and nicotine was significant (P< 0.01). Systemic adminis-
tration of nicotine alone did not significantly alter the
numbers of TH-IR neurons (P> 0.05 compared with con-
trols). To determine whether the protective effect of nico-
tine against MPTP-induced dopaminergic neuronal
degeneration was mediated via α7-nAChRs, mice were
pretreated with the α7-nAChR-selective antagonist MLA
5.0 mg/kg, 30 minutes before nicotine administration.
MLA significantly reversed the protective effect of nico-
tine, as evidenced by a reduction in the numbers of dopa-
minergic neurons by 33.8± 2.3% compared with controls
(P< 0.01; Figure 2B). There were significant differences
between the MLA pretreatment group and the group
treated with both MPTP and nicotine (P< 0.01), but
not between the MLA pretreatment group and the
group treated with MPTP alone (P> 0.05). MLA ad-
ministration alone did not significantly affect the
numbers of TH-IR neurons (P> 0.05 compared with
controls) (Figure 2A,B).
Nicotine acting via α7-nicotinic acetylcholine receptors
inhibits 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-
induced astrocyte activation in the substantia nigra pars
compacta
To evaluate the effects of nicotine on astrocyte activation,
immunostaining was used to detect the astrocyte marker
GFAP. Acute administration of MPTP induced marked
astrocyte activation in the mouse SN (Figure 3A,B), as evi-
denced both by a significant increase in the numbers of
GFAP-IR cells (334.6 ±23.9% increase compared with con-
trols) and by morphological changes such as larger cell
bodies and longer hypertrophic processes (data not shown).
MPTP-induced astrocyte activation and corresponding
increases in the number of GFAP-IR cells were suppressed
by the addition of nicotine. Specifically, nicotine at concen-
trations of 0.25 and 0.5 mg/kg suppressed MPTP-induced
increases in GFAP-IR cells by 38.9± 5.6% and 65.0±3.1%,
respectively (P< 0.01) compared with MPTP treatment
alone. No significant increases in the numbers of GFAP-IR
cells were seen in mice treated with nicotine alone (P> 0.05
compared with controls). Interestingly, the protective effect
of nicotine against astrocyte activation was reversed by pre-
treatment with MLA 5.0 mg/kg (Figure 3A,B). MLA signifi-
cantly reversed nicotinic inhibition of astrocyte activation
by increasing the numbers of GFAP-IR cells to
309.6± 14.2% compared with controls (P< 0.01). There
were significant differences between the MLA pretreatment
group and the group treated with both MPTP and nicotine
(P< 0.01), but there were no significant differences between
the MLA pretreatment group and the group treated with
MPTP alone (P> 0.05). MLA administration alone did not
significantly affect the numbers of GFAP-IR cells (P> 0.05
compared with controls) (Figure 3A,B). These results sug-
gest that nicotine probably inhibits MPTP-induced astro-
cyte activation via its actions at α7-nAChRs.
Nicotine acting via α7-nicotinic acetylcholine receptors
inhibits 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-
induced microglia activation in the substantia nigra pars
compacta
To evaluate the effects of nicotine on microglia activation,
immunostaining was used to detect the microglia marker
Mac-1. Acute administration of MPTP induced marked
microglia activation in the mouse SN (Figure 4A,B), as evi-
denced both by a significant increase in the numbers of
Mac-1-IR cells (247.9±6.6% increase compared with con-
trols) and by the corresponding cellular morphological
changes such as larger cell bodies and poorly ramified short
thick processes. The MPTP-induced microglia activation
and corresponding increases in the numbers of Mac-1-IR
cells were suppressed by the addition of nicotine.
Figure 1 The effects of nicotine on 1-methyl-4-phenyl-1,2,3,
6-tetrahydropyridine (MPTP)-induced mouse motor deficits.
Pole-test scores for each animal were calculated after acute MPTP
treatment at 3 hours, 1 day, 2 days and 7 days. Data are presented
as mean± SEM (n = 10). *P< 0.05 and **P< 0.01 versus the control
(saline alone) group; #P< 0.05 and ##P< 0.01 versus the MPTP
treatment group.
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Specifically, nicotine, at concentrations of 0.25 and
0.5 mg/kg, suppressed MPTP-induced increases in Mac-
IR cells by 27.5± 7.8% and 48.3±9.4%, respectively (P
< 0.01), compared with MPTP treatment alone. No sig-
nificant increases in the numbers of Mac-1-IR cells
were seen in mice treated with nicotine alone (P> 0.05
compared with controls). Interestingly, the protective ef-
fect of nicotine against microglia activation was reversed
by pretreatment with MLA 5.0 mg/kg (Figure 4A,B),
which resulted in an increase in the numbers of Mac-
1-IR cells by 227.0±9.8 % compared with controls (P
< 0.01). There were significant differences between the
MLA pretreatment group and the group treated with
both MPTP and nicotine (P< 0.01), but not between
the MLA pretreatment group and the group treated
with MPTP alone (P> 0.05). MLA administration alone
did not significantly affect the numbers of Mac-1-IR
cells (P> 0.05 compared with controls) (Figure 4A,
B). These results suggest that nicotine probably inhi-
bits MPTP-induced microglia activation via its
actions at α7-nAChRs.
Expression of the α7-nicotinic acetylcholine receptor
subunit in mouse astrocytes
To further test the hypothesis that nicotine-induced
neuroprotection in an MPTP mouse model is
mediated through its actions at α7-nAChRs on astro-
cytes, the expression of α7-nAChRs was evaluated
using primary cultured astrocytes. Cell analyses
showed that more than 95 % of primary cultured
Figure 2 The effects of nicotine on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neuronal loss in the
mouse substantia nigra pars compacta (SNpc). (A) Tyrosine hydroxylase-immunoreactive (TH-IR) neurons in the mouse SNpc. Scale bar:
250 μm. (B) Stereological cell counts of TH-IR neurons in the mouse SNpc. Data are presented as a percentage of controls (mean± SEM) from
four to six mice per group. **P< 0.01 versus the control (saline-only) group; ##P< 0.01 versus the MPTP treatment group.
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mouse astrocytes were GFAP-positive (Figure 5A). To
determine whether α7-nAChR subunits were expressed in
astrocytes, total RNA from primary cultured astrocytes
was first isolated for RT–PCR and real-time PCR analyses.
The results showed that α7-nAChR subunit mRNA
was detected in astrocytes (Figure 5B). The Ct of
glyceraldehyde-3-phosphate dehydrogenase and α7-
nAChR were 11.6 ± 0.2 and 26.6 ± 0.8, respectively.
Fluorescence signals from cells entering the expo-
nential growth phase gave positive results. Further-
more, the α7-nAChR subunit protein was detected by
western blotting in primary cultured astrocytes (Fig-
ure 5C). To evaluate whether α-bungarotoxin, an α7-
nAChR subunit-selective blocker, could bind to this
receptor, we stained primary astrocytes with Alexa
Fluor 488 conjugate-labeled α-bungarotoxin. Strong
binding of α-bungarotoxin was seen on the astrocyte
surface (Figure 5D).
Nicotine acting via α7-nicotinic acetylcholine receptors
decreases 1-methyl-4-phenylpyridinium ion- or
lipopolysaccharide-induced production of tumor necrosis
factor-α from mouse primary cultured astrocytes
The data presented thus far suggest that nicotine,
probably acting at α7-nAChRs, protects dopaminergic
neurons in the mouse SNpc from the effects of acute
Figure 3 The effects of nicotine on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced astrocyte activation in the mouse
substantia nigra pars compacta (SNpc). (A) Glial fibrillary acidic protein immunoreactive (GFAP-IR) astrocytes in mouse SNpc. Scale bar:
250 μm. (B) Stereological cell counts of GFAP-IR astrocytes in the mouse SNpc. Data are presented as a percentage of controls (mean± SEM)
from four to six mice per group. **P< 0.01 versus the control (saline-only) group; ##P< 0.01 versus the MPTP treatment group.
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MPTP treatment. One potential mechanism under-
lying the protective effect of nicotine is that activa-
tion of α7-nAChRs suppresses astrocyte activation
and in turn decelerates or eliminates neuronal in-
flammatory responses. To test this hypothesis, we
evaluated the effects of nicotine on release of the in-
flammatory factor TNF-α induced by MPP+ or the
bacterial endotoxin LPS in cultured mouse astrocytes.
Incubation of cultured mouse astrocytes with MPP+
200 μmol/l or LPS 100 ng/ml for 24 hours signifi-
cantly increased the production of TNF-α (P< 0.01
versus control) (Figure 6A,B). Notably, MPP+
200 μmol/l or LPS 100 ng/ml induced astrocyte acti-
vation but failed to affect astrocyte viability (data not
shown). Pretreatment with nicotine (0.1, 1 or
10 μmol/l) for 30 minutes before the addition of
MPP+ or LPS decreased the production of TNF-α in
a concentration-dependent manner (Figure 6C,D).
Specifically, nicotine 10 μmol/l reduced MPP+- and
LPS-induced production of TNF-α by 58.0 ± 6.7 % (P
< 0.05 versus MPP+ treatment alone) and 88.5 ± 1.7 %
(P< 0.01 versus LPS treatment alone), respectively
(Figure 6C,D). Preincubation with MLA 100 nmol/l
for 30 minutes before administration of nicotine fully
reversed its inhibitory effects (Figure 6E,F). There
were no significant differences between the MLA pre-
treatment group and the groups treated with MPP+
or LPS alone. These results suggest that nicotine
Figure 4 The effects of nicotine on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced microglia activation in the mouse
substantia nigra pars compacta (SNpc). (A) Mac-1-IR microglia in mouse SNpc. Scale bar: 200 μm. (B) Stereological cell counts of Mac-1-IR
microglia in the mouse SNpc. Data are presented as a percentage of controls (mean± SEM) from four to six mice per group. *P< 0.05 and
**P< 0.01 versus the control (saline-only) group; ##P< 0.01 versus the MPTP treatment group.
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significantly abolishes MPP+- or LPS-induced produc-
tion of pro-inflammatory factors from astrocytes via
stimulation of α7-nAChRs.
Nicotine acting via α7-nicotinic acetylcholine receptors
suppresses extracellular regulated kinase1/2 and p38
mitogen-activated protein kinase activation induced by
1-methyl-4-phenylpyridinium ion in astrocytes
MAPKs collectively constitute key signaling molecules
in processes of neuroinflammation. Phosphorylation
of MAPKs leads to the initiation of signal cascades
that regulate the synthesis of a variety of pro-inflammatory
factors such as TNF-α in microglia [12] and astrocytes [6].
In the present study, we investigated whether nicotine
eliminated the MPP+-induced phosphorylation of both
Erk1/2 and p38 MAPKs in astrocyte cultures. Treat-
ment with MPP+ 200 μmol/l induced rapid and tran-
sient phosphorylation of both Erk1/2 and p38,
reflecting their activation, and peak levels of phos-
phorylated Erk1/2 and p38 occurred after 30 minutes
(Figure 7A,B). Levels of phosphorylated Erk1/2 and
p38 were sustained for up to 1 hour after MPP+
treatment. These results suggest that both Erk1/2
and p38 MAPKs are activated in response to MPP+
stimulation in astrocytes. Next, we explored the
effects of nicotine on MPP+-induced Erk1/2 and p38
Figure 5 Expression of the α7-nicotinic acetylcholine receptor (α7-nAChR) subunit expression in primary astrocyte cell cultures. (A)
Glial fibrillary acidic protein (GFAP) immunofluorescence staining of astrocytes in primary cultured astrocyte cells from the midbrain of C57BL/6
black newborn mice 1–2 days after birth. Scale bar: 50 μm. (B) Reverse transcription (RT)-PCR analysis of α7 subunit mRNA expression in primary
cultured astrocyte cells. (C) Western blot of α7 nAChR protein in primary cultured astrocyte cells. (D) Primary mouse astrocytes stained with Alexa
Fluor 488 conjugate-labeled α-bungarotoxin and viewed under fluorescence confocal microscopy. Scale bar: 50 μm.
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MAPK phosphorylation. Pretreatment with 10 μmol/l
nicotine suppressed MPP+-induced increases in the
levels of phosphorylated Erk1/2 and p38 by
32.3 ± 1.7 % (P< 0.01) and 56.4 ± 3.1 % (P< 0.01),
respectively (Figure 7C,D). Moreover, the suppressive
effects of nicotine on Erk1/2 phosphorylation were
completely reversed by 30 minutes of pretreatment
with MLA 100 nmol/l. Interestingly, the suppressive
Figure 6 The effects of nicotine on enhanced production from astrocytes of tumor necrosis factor (TNF)-α induced by 1-methyl-4-
phenylpyridinium ion (MPP+) and lipopolysaccharide (LPS). (A) MPP+ and (B) LPS increased the production of TNF-α in astrocytes. Various
concentrations of nicotine suppressed the otherwise enhanced release of TNF-α induced by (C) 200 μmol/l MPP+ or (D)100 ng/ml LPS in
astrocytes. The α7-nAChR-selective antagonist methyllycaconitine (MLA) abolished the inhibitory effects of nicotine on the release of TNF-α
induced by (E) MPP+ and (F) LPS. Data are presented as a percentage of controls (mean± SEM) of four independent experiments. *P< 0.05 and
**P< 0.01 versus the control group; #P< 0.05 and ##P< 0.01 versus the MPP+ treatment alone group.
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effects of nicotine on p38 phosphorylation were only
partially reversed by MLA. These data suggest that
nicotine acting at α7-nAChRs suppresses MAPK sig-
naling transduction, thereby affecting processes me-
diating neuroinflammation.
Nicotine acting via α7-nicotinic acetylcholine receptors
suppresses lipopolysaccharide-induced extracellular
regulated kinase1/2 and p38 mitogen-activated protein
kinase activation in astrocytes
LPS has been extensively used as a glial activator for
the induction of inflammatory dopaminergic neuro-
degeneration [9]. We examined whether nicotine also
regulated LPS-induced MAPK signaling transduction.
Astrocytes were treated with LPS 100 ng/mL for
different lengths of times to determine the extent of
MAPK activation after LPS stimulation. Treatment
with LPS also led to rapid and transient phosphoryl-
ation of both Erk1/2 and p38, with peak levels simi-
larly occurring at 30 minutes (Figure 8A,B). Levels
of phosphorylated Erk1/2 and p38 were sustained for
up to 2 and 4 hours, respectively, after LPS adminis-
tration. These results suggest that both Erk1/2 and
p38 are activated in response to LPS stimulation in
astrocytes. We then investigated whether nicotine
could regulate LPS-induced Erk1/2 and p38 phos-
phorylation. Pretreatment with nicotine 10 μmol/l
suppressed LPS-induced increases in phosphorylated
Erk1/2 and p38 by 39.6 ± 2.3 % (P< 0.01) and
23.8 ± 5.1 % (P< 0.01), respectively (Figure 8C,D).
Figure 7 The effects of nicotine on activation of extracellular regulated kinase (Erk)1/2 and p38 mitogen-activated protein kinase
(MAPK) induced by 1-methyl-4-phenylpyridinium ion (MPP+) in astrocytes. MPP+ increased Erk1/2 and p38 MAPK phosphorylation indicative
of their activation. (A,B) Astrocytes were treated with MPP+ 200 μmol/l for various lengths of time as indicated.(C,D) Astrocytes were pretreated
with nicotine 10 μmol/l in the absence or presence of MLA 100 nmol/l for 30 minutes and then challenged with MPP+ 200 μmol/l for 30
minutes. After treatment, astrocytes were harvested, and levels of phosphorylated (A,C) Erk1/2 and (B,D) p38 MAPKs were analyzed. Upper panel
shows densitometric analysis of the phosphorylated forms of Erk1/2 and p38 MAPK, while the lower panel shows representative blots. Data are
presented as the mean± SEM of four independent experiments. *P< 0.05 and **P< 0.01 versus the control group; #P< 0.05 and ##P< 0.01 versus
the MPP+ treatment alone group.
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Moreover, the suppressive effects of nicotine on
Erk1/2 and p38 phosphorylation were completely
reversed by MLA (100 nmol/l). These data suggest
that nicotine, through its actions at α7-nAChRs, also
inhibits LPS-induced astrocyte activation via sup-
pression of MAPK signaling transduction.
Discussion
In the brain, two types of glial cells, astroglia and micro-
glia, are the main players in neuroinflammatory pro-
cesses. Microglia, which are resident immune cells
within the brain, are considered to be ‘professional’
macrophages of the CNS. For this reason, most of the
studies of neuroinflammatory processes in the CNS have
focused on microglia. The contribution of astroglia to
these processes often has been neglected. However, re-
cent evidence suggests that astroglia, which represent
the most abundant glial cell population, mediate crucial
neuroinflammatory processes involved in the initiation
and subsequent development of neurodegenerative dis-
orders such as PD [2]. Our results and those obtained
from previous studies identified enhanced immunoreac-
tivity of GFAP-labeled astrocytes in the SN of MPTP-
treated mice, suggesting that reactive astrocytes may
play a key role in brain regions damaged by MPTP [3-5].
Thus, drugs that can regulate astrocyte activation may
potentially exert neuroprotective effects against MPTP/
MPP+-induced toxicity.
In the present study, we found that systemic admin-
istration of nicotine significantly alleviated MPTP-
induced perturbed behavioral symptoms, improved
compromised motor coordination, protected against
degeneration of dopaminergic neurons, and inhibited
activation of astrocytes and microglia in the SN. Fur-
thermore, we found that nicotine suppressed MPP+-
or LPS-stimulated elevation of TNF-α released from
Figure 8 The effects of nicotine on lipopolysaccharide (LPS)-induced Erk1/2 and p38 mitogen-activated protein kinase (MAPK)
activation in astrocytes. LPS also increased Erk1/2 and p38 MAPK phosphorylation, reflecting their activation. (A,B) Astrocytes were treated
with LPS 100 ng/ml for various lengths of time as indicated. (C,D) Astrocytes were pretreated with nicotine 10 μmol/l in the absence or presence
of MLA 100 nmol/l for 30 minutes and then challenged with LPS for 30 minutes. After treatment, astrocytes were harvested, and levels of
phosphorylated (A,C) Erk1/2 and (B,D) p38 MAPK were analyzed. Upper panel shows densitometric analysis of the phosphorylated forms of Erk1/
2 and p38 MAPK, while the lower panel shows representative blots.. Data are presented as the mean± SEM of four independent experiments.
*P< 0.05 and **P< 0.01 versus the control group; #P< 0.05 and ##P< 0.01 versus the LPS treatment alone group.
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reactive astrocytes by downregulating phosphorylation
of Erk1/2 and p38 MAPKs. Erk1/2 [14] and p38 [15]
MAPK pathways were originally identified as signaling
cascades activated by pro-inflammatory stimuli and
cellular stresses, and they have been shown to play
crucial roles in translational regulation of pro-
inflammatory cytokine synthesis. Previous studies have
shown that inhibition of Erk1/2 and p38 MAPKs
reduced expression of inducible nitric oxide synthase
(iNOS) and cyclooxygenase-2 mRNA, suppressed the
production of several pro-inflammatory cytokines in-
cluding TNF-α, and rescued dopaminergic neurons in
the SN [16]. Taken collectively, our data suggest that
the Erk1/2 and p38 MAPK signaling-transduction
pathways are involved in the inhibitory effects of nicotine
on MPP+- or LPS-induced astrocyte activation.
Interestingly, it has been suggested that MPP+ induces
astrocytic apoptosis via regulation of MAPK signaling
[17]. Increasing evidence has shown that astrocytic apop-
tosis may contribute to the pathogenesis of many neuro-
degenerative disorders such as Alzheimer’s disease and
PD [18]. Based upon our findings that nicotine decreased
Erk1/2 and p38 MAPK activation in reactive astrocytes,
further studies are needed to evaluate the potential role
(s) of nicotine in the regulation of astroglial apoptosis.
Epidemiological studies [19] have reported that the
prevalence of PD is lower in smokers than in non-
smokers, leading to the hypothesis that the reduced
prevalence of PD in smokers may be due to the presence
of nicotine in tobacco. Nicotine administration has been
reported to improve motor deficits that arise from
nigrostriatal damage in parkinsonian animals and in
patients with PD. In addition, nicotine has been shown
to exert protective effects against nigrostriatal damage in
various animal models of PD [20,21]. Although these
observations suggest that nicotine may be beneficial for
the treatment of PD, the specific mechanisms underlying
the potentially protective effects of nicotine remain ob-
scure. For example, nicotine may play a neuroprotective
role via modulation of both monoamine oxidase activity
and complex I of the electron transport chain [7]. The
development of studies focused on the neuroprotective
effects exerted by specific nAChR subtypes would be
beneficial, because their identification and the descrip-
tion of their potential roles in the pathogenesis of PD
might facilitate the development of targeted therapies.
The nicotine-induced neuroprotective effects that have
been shown in many animal models might be mediated
via a number of nAChR subtypes, including but not lim-
ited to α4β2 [22], α7 [21], α6α4β2 [23], and α6β2 [24].
Our results showing that nicotine protected against
the loss of dopaminergic neurons in the MPTP-induced
mouse model of PD are consistent with those of several
previous reports [21,25]. However, the mechanisms
underlying nAChR-mediated neuroprotection remain
unknown. nAChRs are transmitter-gated ion channels,
and nine different α subunits (α2 to α10) and three β
subunits (β2 to β4) have been cloned to date [26]. Differ-
ent combinations of α and β subunits, or of α subunits
alone, produce various receptor subtypes that exhibit
different physiologic, pharmacologic, and anatomic
properties. Recently, the α7 subunit has received consid-
erable attention because studies have suggested that it
plays a role in cholinergic anti-inflammatory processes
[27]. Specifically, mounting evidence has shown that
nicotine inhibits inflammatory signaling and the conse-
quent production of relevant pro-inflammatory cyto-
kines via its actions at α7-nAChRs [14,28-30].
In the present study, we found that the alleviation
of MPTP-induced loss of dopaminergic neurons in
the SNpc and inhibition of astrocyte and microglia
activation in the SN by nicotine in vivo was reversed
by the α7-nAChR-selective antagonist MLA. Interest-
ingly however, MLA did not reverse the alleviation
by nicotine of MPTP-induced behavioral symptoms
(data not shown). A more extensive evaluation system
should be used to elucidate more clearly mouse be-
havior in models of PD [31]. Additionally, in mouse
primary cultured astrocytes, pretreatment with nico-
tine suppressed MPP+- or LPS-induced astrocyte acti-
vation, as evidenced by both decreased production of
TNF-α and inhibition of Erk1/2 and p38 MAPK acti-
vation. These inhibitory effects of nicotine were also
reversed by MLA.
The primary cascade activated by the neurotoxin
MPTP in mice might differ depending upon whether
treatment is acute or chronic [32,33]. Liberatore et
al. [4] reported that mutant mice lacking the iNOS
gene were significantly more resistant to acute MPTP
treatment compared with wild-type littermates in an
experiment conducted to investigate the mechanisms
of protection against inflammation. Furuya et al. [32]
examined the role of caspase-11 in inflammation and
apoptosis immediately after MPTP administration in
caspase-11 knockout mice and in their wild-type lit-
termates, and results indicated that the inflammatory
pathway seems to be closely related to the animal
model for acute MPTP treatment. Therefore, we used
an acute MPTP model to investigate the mechanisms
of α7-nAChR-mediated neuroprotection against in-
flammation. There may be changes in receptor kinet-
ics secondary to desensitization and/or possible
receptor downregulation after prolonged nicotine ex-
posure, thus our findings need to be confirmed using
in vivo experiments with chronic exposure, which
more closely resembles the conditions that occur dur-
ing smoking or under therapy with nicotine or nico-
tinic ligands.
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Conclusions
This is the first report that nicotine inhibits MPTP
(in vivo)- and MPP+- or LPS (in vitro)-induced astrocyte ac-
tivation via its actions at α7-nAChRs and decreases the
consequent production of pro-inflammatory factors, thus
alleviating dopaminergic neurodegeneration. Our results
strongly support the hypothesis that inhibition of astrocyte
activation by stimulation of α7-nAChRs may provide a new
therapeutic strategy for treatment of neuroinflammation-
related disorders. Thus, nicotinic agonists that specifically
target the α7-nAChR might serve as potential therapeutic
agents for PD and other neuroinflammation-related neuro-
degenerative diseases.
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